United Therapeutics (UTHR) Non-Current Debt (2010 - 2024)
United Therapeutics (UTHR) posted Non-Current Debt of $100.0 million for Q2 2024, down 50.0% sequentially from $200.0 million in Q1 2024, and down 87.5% YoY from $800.0 million in Q3 2023.
United Therapeutics (UTHR) Non-Current Debt (2010 - 2024) Analysis & Trends
United Therapeutics has reported Non-Current Debt for 13 years, with the latest figure at $100.0 million in Q2 2024.
- Quarterly Non-Current Debt fell 87.5% year-over-year to $100.0 million in Q2 2024, while the trailing twelve-month figure through Jun 2024 was $100.0 million (down 87.5% YoY) and the FY2023 annual result came in at $300.0 million, down 62.5% from the prior year.
- Non-Current Debt fell to $100.0 million in Q2 2024 per UTHR's latest filing, from $200.0 million in the prior quarter.
- Over five years, Non-Current Debt peaked at $800.0 million in Q1 2020 and troughed at $100.0 million in Q2 2024.
- A 5-year average of $683.3 million and a median of $800.0 million in 2020 frame the typical range for Non-Current Debt.
- The sharpest annual moves came in 2020 and 2024: Non-Current Debt soared 33.33% in 2020, then sank 87.5% in 2024.
- Over 5 years, Non-Current Debt stood at $800.0 million in 2020, then changed by 0.0% to $800.0 million in 2021, then changed by 0.0% to $800.0 million in 2022, then slumped by 62.5% to $300.0 million in 2023, then slumped by 66.67% to $100.0 million in 2024.
- According to Business Quant data, Non-Current Debt over the past three periods registered $100.0 million, $200.0 million, and $300.0 million for Q2 2024, Q1 2024, and Q4 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - | -8.44 Bn |
| 2 | Teva Pharmaceutical Industries | 43.42 Bn | 39.76 Bn | 2.15 Bn | 12.09 Bn |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn | 9.05 Bn |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.98 Bn | 5.10 Bn | 27.73 Bn |
| 5 | United Therapeutics | 22.29 Bn | 19.63 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.78 Bn | 17.89 Bn | 1.46 Bn | 11.61 Bn |
| 7 | Neurocrine Biosciences | 15.66 Bn | 15.27 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.91 Bn | 11.38 Bn | 798.00 Mn | 3.85 Bn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - | 130.00 Mn |
| 10 | Alkermes | 8.20 Bn | 7.55 Bn | 397.90 Mn | 1.48 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 100.00 Mn |
| Mar 31, 2024 | 200.00 Mn |
| Dec 31, 2023 | 300.00 Mn |
| Sep 30, 2023 | 500.00 Mn |
| Jun 30, 2023 | 800.00 Mn |
| Mar 31, 2023 | 800.00 Mn |
| Dec 31, 2022 | 800.00 Mn |
| Sep 30, 2022 | 800.00 Mn |
| Jun 30, 2022 | 800.00 Mn |
| Mar 31, 2022 | 800.00 Mn |
| Dec 31, 2021 | 800.00 Mn |
| Sep 30, 2021 | 800.00 Mn |
| Jun 30, 2021 | 800.00 Mn |
| Mar 31, 2021 | 800.00 Mn |
| Dec 31, 2020 | 800.00 Mn |
| Sep 30, 2020 | 800.00 Mn |
| Jun 30, 2020 | 800.00 Mn |
| Mar 31, 2020 | 800.00 Mn |
| Dec 31, 2019 | 600.00 Mn |
| Sep 30, 2019 | 750.00 Mn |